Pangea Bio*, a company developing transformative medicines for neurological disorders, has been accepted to join the One Mind Accelerator.

One Mind is a leading mental health nonprofit committed to healing the lives of people impacted by mental illness through global, collaborative action.

The One Mind Accelerator backs visionary founders of early-stage startups with the network, education, and capital to rapidly build category-defining companies that improve the lives of people living with mental illness.

Pangea is one of 10 companies selected for the program, which seeks to address the global mental health crisis with a sense of urgency and at scale through the power of entrepreneurship. Each selected company will be granted a $100,000 investment and will participate in a rigorous 9-week program specifically designed to empower founders to scale their business and ultimately elevate their companies to new heights.

One Mind leverages its vast and prestigious network of world-class investors, founders, operators, scientists, payers, providers, policymakers, and lived experience advocates to accelerate the path to success for companies part of their Accelerator.

Pangea Bio’s CEO Lars Wilde said: “We are really excited about the opportunities and value that working with One Mind and its wider network will bring to Pangea Bio, as we look to rapidly advance our transformative treatments for the most serious and debilitating of neurological and psychiatric conditions.”

For more information, please contact info@pangeabio.com

* Pangea Bio is a trading name of Pangea Botanica Ltd